ERBB2 and breast cancer: These findings raise the importance of identifying molecular profiling of ER, PR, Her2/neu and the state of BRCA1 expression as useful prognostic markers for BC patients before starting treatment and selecting proper persons for the genetic screening of the mutated BRCA1 oncoprotein.